UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...
They found that the proportion of patients younger than 50 admitted to the hospital with severe diverticulitis increased by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback